Valuation: PureTech Health plc

Market Cap 423M 372M 343M 320M 601M 39.95B 612M 4.11B 1.59B 19.69B 1.59B 1.55B 68.43B P/E 2026 *
-3.79x
P/E 2027 * -4.2x
Enterprise Value 185M 162M 150M 140M 262M 17.45B 267M 1.8B 696M 8.6B 694M 679M 29.89B EV / Sales 2026 *
26x
EV / Sales 2027 * 14.2x
Free-Float
84.5%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week-1.05%
Current month-6.33%
1 month-7.26%
3 months+13.45%
6 months+1.73%
Current year+4.01%
1 week 126.2
Extreme 126.2
135.6
1 month 121.6
Extreme 121.6016
143.6
Current year 107.4
Extreme 107.4
143.6
1 year 104.71
Extreme 104.712
148
3 years 100.4
Extreme 100.4
238.5
5 years 100.4
Extreme 100.4
410.66
10 years 100.4
Extreme 100.4
447.66
Manager TitleAgeSince
Chief Executive Officer 43 2025-07-14
President 53 2024-04-08
Chief Operating Officer - 2021-07-31
Director TitleAgeSince
Director/Board Member 76 2015-05-07
Director/Board Member 76 2008-12-31
Director/Board Member 73 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
03-12Buy

Founder

112,509 0.0466%
25-09-23Buy

Chairman

65,250 0.0272%
25-09-23Buy

Director

59,100 0.0246%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-1.05%+1.26%-41.17% 423M
-0.35%+7.12%-5.15%+2.38% 46.36B
+4.95%+9.31%+363.86%+598.16% 37.88B
+0.44%+11.12%+17.47%-12.91% 31.12B
-0.64%+1.92%+3.08%+53.58% 30.61B
+0.23%-0.29%+13.24%+21.10% 24.69B
+9.90%+13.32% - - 16.25B
+1.40%+12.99%+67.11%+132.76% 14.85B
+0.06%+9.21%+12.19%+21.62% 13.58B
+2.38%+5.69%+95.85%+97.63% 12.95B
Average +1.67%+7.51%+63.21%+97.02% 22.87B
Weighted average by Cap. +1.66%+7.99%+79.60%+131.97%

Financials

2026 *2027 *
Net sales 7.1M 6.24M 5.75M 5.37M 10.08M 670M 10.26M 68.94M 26.7M 330M 26.66M 26.08M 1.15B 13.47M 11.83M 10.9M 10.19M 19.11M 1.27B 19.46M 131M 50.65M 626M 50.57M 49.46M 2.18B
Net income -124M -109M -101M -94.19M -177M -11.74B -180M -1.21B -468M -5.79B -467M -457M -20.12B -97.27M -85.44M -78.72M -73.6M -138M -9.18B -141M -944M -366M -4.52B -365M -357M -15.72B
Net Debt -238M -209M -193M -180M -338M -22.5B -345M -2.31B -897M -11.09B -895M -876M -38.54B -232M -204M -188M -176M -330M -21.92B -336M -2.26B -874M -10.8B -872M -853M -37.54B
Logo PureTech Health plc
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Employees
90
Date Price Change Volume
26-06-26 GBX 130.02 -1.20% 15,077
26-06-25 GBX 131.60 -1.94% 474,718
26-06-24 GBX 134.20 +1.67% 267,618
26-06-23 GBX 132.00 -0.45% 261,827
26-06-22 GBX 132.60 +0.91% 400,103
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.739USD
Average target price
5.151USD
Spread / Average Target
+196.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTC Stock